GU Cancers 2023 | Highlights in prostate cancer at ASCO GU 2023

Anthony Victor D’Amico, MD, PhD, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA, discusses the Phase II FORMULA-509 trial (NCT03141671) and its implications for clinical practice, as well as the Phase III CHHiP trial and possible concerns about second-cancer risk. Prof. D’Amico also discusses possible quality-of-life benefits with the use of SBRT compared to radical prostatectomy. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.